Who Paid My Doc
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433
ClinicalTrials.gov NCT03345823
Research payments
$2,186,661
Through program year 2021, $2,186,661 in research payments was reported against A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433, across 519 payments, paid by AbbVie, Inc..
- Paid by
- AbbVie, Inc.
- ClinicalTrials.gov
- NCT03345823
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $2,186,661 | 519 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- John Ferry Omaha, NE Named on 20 payments
- Adam Steinlauf New York, NY Named on 19 payments
- Jonathan Siegel Mobile, AL Named on 16 payments
- Baldeep Pabla Nashville, TN Named on 14 payments
- George Duvall Vero Beach, FL Named on 14 payments
- Edward Loftus Rochester, MN Named on 13 payments
- Charles Johnson Mobile, AL Named on 13 payments
- Peter Higgins Ann Arbor, MI Named on 12 payments
- Loren Brook Cincinnati, OH Named on 12 payments
- Harvey Tatum Tulsa, OK Named on 12 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.